EGFR and cancer: The recent discovery of small-molecule tyrosine kinase inhibitors (TKIs) has led to favorable cancer profile drugs that target cancer-specific EGFR inhibitors such as gefitinib and erlotinib lapatinib, afatinib, canertinib, and angiogenesis inhibitors such as sorafenib, sunitinib, and axitinib.